Tag Archive for: Parkinson’s disease

Alpha-Synuclein staining of a Lewy body in the substantia nigra in Parkinson's disease.Marvin 101 - wikipedia.org
Licence deal

Novartis AG invests US$200m in lacklustre Parkinson’s target

Swiss pharma major Novartis AG is investing money in the inhibition of the Parkinson’s target alpha-synuclein, which has already failed several times in clinical trials. The Swiss company is licensing the siRNA programme ARO-SNCA from Arrowhead Pharmaceuticals for US$200m.

Read more
Forbion Venture Partner and Vitala Bio founder Matt CooperForbion
Licence deal

SitalaBio pays US$670m for Fosun inflammation blocker

British company Sitala Bio Ltd, founded in 2021 by NLRP3 inflammasome expert Matt Cooper, is paying US$670m and giving up to 10% of its shares to Chinese company Shanghai Fosun Pharmaceutical Group Co. Ltd. in exchange for the development and marketing rights to the low-molecular-weight inflammation blocker FXS6837.

Read more
Prof Dr Klaus Gerwert is the founding managing director of PRODI - Centre for Protein Research at Ruhr-Universität Bochum - and CEO of betaSENSE.Marquard - Ruhr University Bochum
Parkinson's disease

betaSense GmbH identifies new diagnostic biomarker for Parkinson’s

A new biomarker for Parkinson’s disease makes it possible to recognise and treat the hereditary dopamine deficiency before the mid-brain is damaged, reports University Bochum spin-out betaSense GmbH.

Read more